Immuneering Corporation
IMRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Immuneering Corporation (IMRX) is listed under Biotechnology. The $309.3M market capitalization puts IMRX squarely in small-cap range for its industry. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Market Cap
$309.3M
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
-3.81
EPS (TTM)
$-0.93
EPS (Fwd)
$-1.26
ROE
-52.1%
ROA
-32.8%
Cash
$149.9M
Total Debt
$3.6M
Free CF
-$39.4M
52W Change
-40.8%
Annual Financials
Cash vs Debt
Where IMRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IMRX finished 0.60% above its 150-day moving average ($4.99) and 4.74% below its 200-day moving average ($5.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMRX overbought or oversold?
At the September 3, 2026 close, IMRX's RSI(14) was 44.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $149.9M in cash comfortably exceeding the $3.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$39.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -52.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $317K (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Immuneering Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, IMRX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMRX.